We invite everyone to join us to learn about a cancer therapy guidance test designed to predict which cancer drugs are most likely to be effective for individual cancer patients. Cancer Commons is partnering with Travera with the shared goal of helping late-stage cancer patients who are running out of therapeutic options and time.
A New Technology for Rapid Therapy Guidance will be held December 14, 2022 at 12:00 PM PT / 3:00 PM ET.
While the FDA has approved many drugs to treat specific cancers, every cancer patient’s cells are unique. Not all approved drugs work for all people at every cancer stage. Travera uses a single-cell measurement technology invented at MIT to measure the ex vivo growth response of live tumor cells to candidate drugs. Their 2-day Rapid Therapy Guidance™ test enables patients who are running out of therapeutic options to discover additional options and continue their battle against cancer.
To register for A New Technology for Rapid Therapy Guidance, please click here.
